News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boston Therapeutics, Inc. Completes Human Clinical Study with SUGARDOWN(TM) at Boston Therapeutics, Inc.


8/18/2011 9:51:25 AM

MANCHESTER, N.H.--(BUSINESS WIRE)--Boston Therapeutics, Inc. (BTI), a public company registered with the SEC and a developer of diabetes therapeutics, announced today the completion of a trial in healthy volunteers performed at the University of Sydney on SUGARDOWN™, a dietary supplement designed to reduce post-meal elevation of blood glucose.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES